- 全部删除
- 您的购物车当前为空
Letaplimab (IBI-188) 是一种靶向 CD47 的人源化IgG4类抗体,常联合阿扎胞苷治疗初诊中高危骨髓增生异常综合症。
Letaplimab (IBI-188) 是一种靶向 CD47 的人源化IgG4类抗体,常联合阿扎胞苷治疗初诊中高危骨髓增生异常综合症。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 1,980 | In stock | |
5 mg | ¥ 4,980 | In stock | |
10 mg | ¥ 6,880 | In stock | |
25 mg | ¥ 9,870 | In stock |
产品描述 | Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes. |
别名 | 莱特利单抗, IBI-188, IBI188 |
CAS No. | 2283356-07-8 |
存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容